INSTATAB Trademark

Trademark Overview


On Monday, July 17, 2006, a trademark application was filed for INSTATAB with the United States Patent and Trademark Office. The USPTO has given the INSTATAB trademark a serial number of 78931095. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 25, 2011. This trademark is owned by Biovail Laboratories International SRL. The INSTATAB trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and al...
instatab

General Information


Serial Number78931095
Word MarkINSTATAB
Filing DateMonday, July 17, 2006
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 25, 2011
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 1, 2008

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of depression; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the immune system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculo-skeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, pain relief medication and anti-inflammatories; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances, namely, medicated skin care preparations for use in dermatology, namely, dermatitis and skin pigmentation diseases; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in ophthalmology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the prevention, treatment and alleviation of circulatory, neurologic, alimentary, auto-immune, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral, urinary, renal, infectious or metabolic diseases, illnesses, disorders or conditions; metformin; diltiazem; tramadol; carvedilol; bupropion; metoprolol; citalopram; zolpidem; fluoxetine; venlafaxine; lorazepam; and sumatriptan; rapidly dissolving drug delivery agents consisting of compounds that facilitate the delivery of a wide variety of pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 21, 2006
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiovail Laboratories International SRL
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressChrist Church BB17154
BB

Party NameBiovail Laboratories International SRL
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressSt. Michael
BB

Trademark Events


Event DateEvent Description
Wednesday, January 22, 2014ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, January 22, 2014TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 25, 2011ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, April 25, 2011ABANDONMENT - NO USE STATEMENT FILED
Wednesday, April 6, 2011ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, March 23, 2011ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, October 13, 2010ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Saturday, October 2, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 1, 2010EXTENSION 5 GRANTED
Tuesday, September 21, 2010EXTENSION 5 FILED
Tuesday, September 21, 2010TEAS EXTENSION RECEIVED
Tuesday, April 13, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 12, 2010EXTENSION 4 GRANTED
Wednesday, March 17, 2010EXTENSION 4 FILED
Monday, April 12, 2010CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, March 17, 2010TEAS EXTENSION RECEIVED
Friday, September 18, 2009EXTENSION 3 GRANTED
Tuesday, September 15, 2009EXTENSION 3 FILED
Tuesday, September 15, 2009TEAS EXTENSION RECEIVED
Wednesday, June 17, 2009ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, April 8, 2009EXTENSION 2 GRANTED
Tuesday, March 24, 2009EXTENSION 2 FILED
Wednesday, April 8, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 24, 2009TEAS EXTENSION RECEIVED
Thursday, January 22, 2009APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, January 22, 2009TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, September 19, 2008EXTENSION 1 GRANTED
Friday, September 19, 2008EXTENSION 1 FILED
Friday, September 19, 2008TEAS EXTENSION RECEIVED
Tuesday, March 25, 2008NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 5, 2008CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, February 5, 2008ASSIGNED TO EXAMINER
Monday, January 14, 2008FAX RECEIVED
Tuesday, January 1, 2008PUBLISHED FOR OPPOSITION
Wednesday, December 12, 2007NOTICE OF PUBLICATION
Friday, November 23, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, November 23, 2007ASSIGNED TO LIE
Thursday, October 18, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, September 29, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 27, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 27, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 27, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 27, 2007TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, March 28, 2007FINAL REFUSAL E-MAILED
Wednesday, March 28, 2007FINAL REFUSAL WRITTEN
Saturday, March 10, 2007TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 9, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 9, 2007TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 13, 2006NON-FINAL ACTION E-MAILED
Wednesday, December 13, 2006NON-FINAL ACTION WRITTEN
Wednesday, December 13, 2006ASSIGNED TO EXAMINER
Friday, July 21, 2006NEW APPLICATION ENTERED IN TRAM